Efficacy and safety of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Central Precocious Puberty

Efficacy and safety of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Central Precocious Puberty


چاپ صفحه
پژوهان
صفحه نخست سامانه
نویسندگان
نویسندگان
اطلاعات تفضیلی
اطلاعات تفضیلی
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: سیامک شیوا

عنوان کنگره / همایش: 16 امین کنگره غدد و متابولیسم کودکان , Iran (Islamic Republic) , کرمان , 2023

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله سیامک شیوا
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات سلامت کودکان
کد مقاله 82449
عنوان فارسی مقاله Efficacy and safety of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Central Precocious Puberty
عنوان لاتین مقاله Efficacy and safety of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Central Precocious Puberty
نوع ارائه پوسترو سخنرانی
عنوان کنگره / همایش 16 امین کنگره غدد و متابولیسم کودکان
نوع کنگره / همایش ملی
کشور محل برگزاری کنگره/ همایش Iran (Islamic Republic)
شهر محل برگزاری کنگره/ همایش کرمان
سال انتشار/ ارائه شمسی 1402
سال انتشار/ارائه میلادی 2023
تاریخ شمسی شروع و خاتمه کنگره/همایش 1402/02/27 الی 1402/02/29
آدرس لینک مقاله/ همایش در شبکه اینترنت
آدرس علمی (Affiliation) نویسنده متقاضی Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

نویسندگان
hide/show

نویسنده نفر چندم مقاله
سیامک شیوااول

اطلاعات تفضیلی
hide/show

عنوان متن
خلاصه مقالهIntroduction: Gonadotrophin releasing hormone analogues (GnRHas) have been the gold standard therapy for central precocious puberty (CPP) for more than 30 years. These drugs suppress gonadotropin secretion through the desensitization and downregulation of GnRH receptors by exposing them to continuous rather than pulsatile GnRH release, leading to the decrease in gonadal steroid levels to prepubertal levels. GnRH Analogs:In the early 1980s, several different formulations of GnRHas were developed with different durations of action and routes of administration. The 1-month depot formulation of GnRH analogue is the primary formulation used in the treatment of CPP. It provides a steady release of the drug and significantly improves the short-and long-term outcomes in children affected by CPP without adverse effects during and after the treatment. During the past decade there has been a substantial increase in the number of extended-release formulations of GnRHas. Triptorelin: Triptorelin is a synthetic GnRH agonist, first registered in France in 1986. Triptorelin has been widely used in its 3.75 mg formulation for CPP, which is administered every 28 days. A new depot formulation is now available at a dose of 11.25 mg which produces a slow kinetic release over 3 months. Summary: Pharmacodynamic effects of long-acting triptorelin 3-month are similar to those previously reported with the monthly formulation of the same drug. Efficacy of long-acting triptorelin 3-month is comparable to 1-month depot regarding hormonal suppression and inhibition of bone maturation.Long-acting triptorelin 3-month formulation (11.25 mg) may improve compliance and injection monitoring, leading to better short- and long-term outcome of children with CPP.
کلمات کلیدیTriptorelin 3-Month Central Precocious Puberty Gonadotrophin releasing hormone analogues

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
Dr.Shiva.pdf1402/06/16139726دانلود
Certificate. Dr.shiva.pdf1402/06/16186110دانلود